CAJ | 학술논문

　　原发性肝癌是我国常见的恶性肿瘤之一，化疗是中晚期肝癌综合治疗的重要手段，但肝癌化疗多药耐药现象严重阻碍了化疗的效果。目前肝癌多药耐药的机制仍不明确，主要包括跨膜转运蛋白泵药作用，细胞内酶系统改变，MAPK信号转导系统的激活，控制凋亡的基因和蛋白的改变，肿瘤微环境的影响等。近年随着研究的不断深入，又有新的相关机制报道，如内质网应激和microRNA在肝癌耐药中发挥着不可忽视的作用。本文就近年来肝癌多药耐药的相关研究进展做简要综述，为临床提供新的思路。
　　원발성간암시아국상견적악성종류지일，화료시중만기간암종합치료적중요수단，단간암화료다약내약현상엄중조애료화료적효과。목전간암다약내약적궤제잉불명학，주요포괄과막전운단백빙약작용，세포내매계통개변，MAPK신호전도계통적격활，공제조망적기인화단백적개변，종류미배경적영향등。근년수착연구적불단심입，우유신적상관궤제보도，여내질망응격화microRNA재간암내약중발휘착불가홀시적작용。본문취근년래간암다약내약적상관연구진전주간요종술，위림상제공신적사로。
Hepatocellular carcinoma (HCC) is one of the common malignant tumors in China. The most important treatment for middle-late stage HCC is chemotherapy. However, the development of multidrug resistance (MDR) in HCC can dramatically reduce the efficacy of chemotherapeutic treatment. At present, the mechanisms regulating the development of MDR in HCC are still unknown. These mechanisms involve ATP-dependent drug efflux pump, enzymatic deactivation, the activation of MAPK signal pathway, apoptosis gene and protein changing, the influence of the tumor microenvironment, and so on. With the development of the research, some new mechanisms are found, such as the endoplasmic reticulum stress and the effect of microRNA, which cannot be ignored. This review aims to summarize the mechanisms of MDR in HCC and discuss potential therapeutic targets for anticancer intervention.